Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development with Digital Pathology
WILMINGTON, MA and DUBLIN, Ireland March 30 2020 — Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software as a service.
Pathology is typically regarded as a diagnostically complex, process heavy discipline. The advent of digital pathology was viewed as having high potential for delivering great productivity enhancement, however that potential ha s yet to be fully realized.
By combining ergonomic digital pathology workflows with artificial intelligence, Deciphex’s Patholytix Preclinical platform can help maximize pathologist productivity and deliver quality data to clients faster.
Deciphex’s flagship product, Patholytix Preclinical is an industry recognized technology for developing a streamlined workflow that empowers pathologists to generate primary diagnostic or peer review results from their computer workstation faster than would be possible either with traditional microscopy processes or with stand alone digital pathology software.
Through this agreement in addition to Charles River being the exclusive contract research organization distributing the Patholytix Preclinical solution to clients , the organizations will work together to co develop deep learning enabled tools to support accelerated pathology analytics. By combining Deciphex’s unique digital pathology solutions with Charles River’s streamlined integrated drug discovery and development portfolio, Charles River clients will have access to an increasingly efficient, best in class platform.
Our pathologists are the best in the industry—and in 2019, they examined over 4 million pathology slides. By providing them with the Deciphex solutions, we are giving them access to innovative tools that will provide valuable insights to clients earlier in the analysis phase.
Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River
Charles River offers the most robust preclinical pathology program in the industry. By partnering with their team, the use of the Deciphex technology will provide an incredible opportunity to positively influence the outcome of a significant component of the industry’s pre-clinical pathological samples.
Donal O’Shea, Founder and Chief Executive Officer at Deciphex
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
About Deciphex
Deciphex are an Irish-based software company focused on developing digital pathology software for clinical and toxicologic pathology. Our ambition is to deliver solutions that provide tangible improvements in productivity to pathologists, eliminating low-level tasks so they can focus on the critical content. We believe that digital pathology combined with artificial intelligence will help make pathologists work more efficiently in the future and offers a solution to the pending crisis in supply/demand in pathology services.
Deciphex plans to be at the forefront of this revolution with cleverly positioned solutions, that deliver on the biggest problems facing pathology today. To learn more about our innovative digital pathology platform, visit www.deciphex.com.
Source: Deciphex
